NAPIGEN is a biotechnology company focused on harnessing the power of mitochondria and chloroplasts through unique organelle genome editing tools. The company operates in the agriculture, human healthcare, and industrial biotechnology markets. In agriculture, NAPIGEN's products aim to increase grain yields and mitigate greenhouse gases. In healthcare, the company is developing gene editing technologies to treat severe human diseases caused by mitochondrial DNA mutations, such as Kearns-Sayre syndrome and Leber Hereditary Optic Neuropathy. NAPIGEN's business model involves leveraging its proprietary technology to create high-value products and solutions, generating revenue through product sales and potential licensing agreements. The company serves clients in the agricultural sector, healthcare providers, and industrial biotech firms.

Keywords: genome editing, mitochondria, chloroplasts, agriculture, healthcare, biotechnology, grain yields, greenhouse gases, mitochondrial diseases, biofactories.